#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease – Circulation

News Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology

Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine

Commentary on Twitter

#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w… https://t.co/9g97s4MZSt pic.twitter.com/y5uN53gdKo

— Circulation (@CircAHA) August 29, 2022